JP2015505823A5 - - Google Patents

Download PDF

Info

Publication number
JP2015505823A5
JP2015505823A5 JP2014543617A JP2014543617A JP2015505823A5 JP 2015505823 A5 JP2015505823 A5 JP 2015505823A5 JP 2014543617 A JP2014543617 A JP 2014543617A JP 2014543617 A JP2014543617 A JP 2014543617A JP 2015505823 A5 JP2015505823 A5 JP 2015505823A5
Authority
JP
Japan
Prior art keywords
amyloid
variant
polypeptide
pharmaceutical composition
wild
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014543617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505823A (ja
JP6220344B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/066793 external-priority patent/WO2013082114A1/en
Publication of JP2015505823A publication Critical patent/JP2015505823A/ja
Publication of JP2015505823A5 publication Critical patent/JP2015505823A5/ja
Application granted granted Critical
Publication of JP6220344B2 publication Critical patent/JP6220344B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014543617A 2011-11-29 2012-11-28 アミロイド結合剤としてのバクテリオファージのｐ３の使用 Active JP6220344B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161564602P 2011-11-29 2011-11-29
US61/564,602 2011-11-29
US201261708709P 2012-10-02 2012-10-02
US61/708,709 2012-10-02
US201261730316P 2012-11-27 2012-11-27
US61/730,316 2012-11-27
PCT/US2012/066793 WO2013082114A1 (en) 2011-11-29 2012-11-28 Use of p3 of bacteriophage as amyloid binding agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017074284A Division JP6440765B2 (ja) 2011-11-29 2017-04-04 アミロイド結合剤としてのバクテリオファージのｐ３の使用

Publications (3)

Publication Number Publication Date
JP2015505823A JP2015505823A (ja) 2015-02-26
JP2015505823A5 true JP2015505823A5 (https=) 2015-12-03
JP6220344B2 JP6220344B2 (ja) 2017-10-25

Family

ID=47326403

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014543617A Active JP6220344B2 (ja) 2011-11-29 2012-11-28 アミロイド結合剤としてのバクテリオファージのｐ３の使用
JP2017074284A Active JP6440765B2 (ja) 2011-11-29 2017-04-04 アミロイド結合剤としてのバクテリオファージのｐ３の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017074284A Active JP6440765B2 (ja) 2011-11-29 2017-04-04 アミロイド結合剤としてのバクテリオファージのｐ３の使用

Country Status (16)

Country Link
US (3) US9493515B2 (https=)
EP (1) EP2785364B1 (https=)
JP (2) JP6220344B2 (https=)
KR (1) KR20140100543A (https=)
CN (2) CN114748605A (https=)
AU (1) AU2012346056B2 (https=)
BR (1) BR112014013086A2 (https=)
CA (1) CA2857539C (https=)
EA (2) EA029602B1 (https=)
IL (1) IL232867B (https=)
IN (1) IN2014CN04587A (https=)
MX (1) MX362175B (https=)
PH (1) PH12014501200A1 (https=)
SG (2) SG11201402425TA (https=)
WO (1) WO2013082114A1 (https=)
ZA (1) ZA201403863B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114748605A (zh) * 2011-11-29 2022-07-15 普罗克拉拉生物科学股份有限公司 噬菌体基因3蛋白组合物及作为淀粉样蛋白结合剂的用途
CN104870008B (zh) 2012-10-02 2019-10-01 普罗克拉拉生物科学股份有限公司 噬菌体的p3融合蛋白作为淀粉样蛋白结合剂的用途
KR20160010618A (ko) * 2013-05-28 2016-01-27 뉴로페이지 파마슈티컬즈, 인크. 감소된 면역원성을 갖는 개질된 박테리오파아지 g3p 아미노산 서열을 포함하는 폴리펩티드
PL3227313T3 (pl) 2014-12-03 2022-05-09 Proclara Biosciences, Inc. Polipeptydy zawierające zmodyfikowaną sekwencję aminokwasową bakteriofaga g3p pozbawioną sygnału glikozylacji
CA3003911C (en) * 2015-11-25 2021-05-04 Eli Lilly And Company Phage display vectors and methods of use
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3652507B1 (en) * 2017-07-14 2023-06-07 GCE Holding AB Electronic gauge
EP3806884B1 (en) * 2018-06-15 2023-08-02 Amyl Therapeutics General amyloid interaction motif (gaim)
CN120641092A (zh) 2022-12-02 2025-09-12 阿尔泽恩股份有限公司 用于用曲米沙特治疗神经变性病症的方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
ATE194384T1 (de) 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
DK0575545T3 (da) 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE69334070T2 (de) 1992-05-26 2007-01-04 Immunex Corp., Thousand Oaks Neue zytokine die cd30 binden
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
US7189830B2 (en) 2001-02-19 2007-03-13 Merck Patent Gmbh Anti-KSA/IL-2 fusion proteins with reduced immunogenicity
MXPA03008032A (es) 2001-03-08 2003-12-04 Merck Patent Gmbh Factor de estimulacion de colonias de granulocitos- macrofagos modificado con inmunogenicidad reducida.
DE10238846A1 (de) 2002-08-20 2004-03-04 Nemod Immuntherapie Ag Aktive Fusionsproteine und Verfahren zu ihrer Herstellung
EP1532265A2 (de) 2002-08-20 2005-05-25 Sungene GmbH & Co. KGaA Verfahren zur herstellung von ketocarotinoiden in genetisch veränderten organismen
EP1853285B1 (en) 2005-02-01 2011-03-16 Ramot at Tel-Aviv University Ltd. Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia
SG10201404801YA (en) * 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
MX2008010612A (es) 2006-02-15 2009-03-20 Ramot At Tel Aviv University Bacteriofago filamentoso que exhibe proteina a como aglutinante de anticuerpos e inmunocomplejos para el suministro hacia el cerebro.
US20090304726A1 (en) 2006-02-15 2009-12-10 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
WO2007109733A2 (en) * 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
WO2007114139A1 (ja) 2006-04-06 2007-10-11 Fumiaki Uchiyama 新規繊維状ファージによるファージディスプレイ
EP2054515B1 (en) 2006-07-21 2012-01-11 Ramot at Tel-Aviv University Ltd. Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
EP2080138A2 (en) 2006-10-11 2009-07-22 Antitope Limited T cell epitope databases
WO2009143470A1 (en) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method for treating disease characterized by plaque
JP2011529084A (ja) * 2008-07-25 2011-12-01 アボット・ラボラトリーズ アミロイドβペプチド類似体、これらのオリゴマー、前記類似体またはオリゴマーを調製するためのプロセスおよび前記類似体またはオリゴマーを含む組成物ならびにこれらの使用
EP2356231A2 (en) * 2008-09-26 2011-08-17 Wyeth LLC Compatible display vector systems
RU2011125971A (ru) 2008-11-24 2012-12-27 Рамот Эт Тель-Авив Юниверсити Лтд. Способ лечения болезни паркинсона
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
US8856364B2 (en) 2011-03-11 2014-10-07 Google Inc. Conducting opportunistic network updates on a mobile device
BR112013023040A2 (pt) 2011-03-11 2018-10-23 Univ Ramot bacteriófago filamentoso, composição farmacêutica, e, métodos para reduzir a formação de fibrilas de proteína tau ou para desagregar fibrilas pré-formadas de proteína tau em um paciente, e para tratar uma tauopatia degenerativa.
CN114748605A (zh) 2011-11-29 2022-07-15 普罗克拉拉生物科学股份有限公司 噬菌体基因3蛋白组合物及作为淀粉样蛋白结合剂的用途
CN104870008B (zh) 2012-10-02 2019-10-01 普罗克拉拉生物科学股份有限公司 噬菌体的p3融合蛋白作为淀粉样蛋白结合剂的用途
KR20160010618A (ko) 2013-05-28 2016-01-27 뉴로페이지 파마슈티컬즈, 인크. 감소된 면역원성을 갖는 개질된 박테리오파아지 g3p 아미노산 서열을 포함하는 폴리펩티드
PL3227313T3 (pl) 2014-12-03 2022-05-09 Proclara Biosciences, Inc. Polipeptydy zawierające zmodyfikowaną sekwencję aminokwasową bakteriofaga g3p pozbawioną sygnału glikozylacji

Similar Documents

Publication Publication Date Title
JP2015505823A5 (https=)
Eck et al. Regulation of TDP-43 phosphorylation in aging and disease
Scheckel et al. Prions, prionoids and protein misfolding disorders
Moreth et al. Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?
Kim et al. BRI2 (ITM2b) inhibits Aβ deposition in vivo
JP6283366B2 (ja) アミロイド結合剤としてのバクテリオファージ融合タンパク質のｐ３の使用
Neff et al. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders
JP6220344B2 (ja) アミロイド結合剤としてのバクテリオファージのｐ３の使用
Sharma et al. Effect of disease-associated P123H and V70M mutations on β-synuclein fibrillation
Roque et al. Histone H1 favors folding and parallel fibrillar aggregation of the 1–42 Amyloid-β Peptide
Eigenbrod et al. Substitutions of PrP N-terminal histidine residues modulate scrapie disease pathogenesis and incubation time in transgenic mice
Daude et al. Wild‐type Shadoo proteins convert to amyloid‐like forms under native conditions
Southwell et al. Antibody therapy in neurodegenerative disease
Barreca et al. Therapeutic Trajectories in Human Prion Diseases
Paganetti et al. Transgenic expression of β1 antibody in brain neurons impairs age-dependent amyloid deposition in APP23 mice
Zaccagnini In silico and in vitro screening of acridine and phenothiazine derivatives as anti-prion agents
CN120153082A (zh) 展示靶向β淀粉样蛋白的肽基序的M13噬菌体、其方法和用途
Noble Biochemical and Structural Studies of Prion Protein Misfolding
RS56559B1 (sr) Upotreba p3 fuzionih proteina bakteriofaga kao vezujućih agenasa amiloida
HK1213775B (en) Use of p3 of bacteriophage fusion proteins as amyloid binding agents
HK1197655A (en) Use of p3 of bacteriophage as amyloid binding agents
HK1197655B (en) Use of p3 of bacteriophage as amyloid binding agents